A new model of neurogenic hypertension caused by renal injury: Pathophysiology and therapeutic implications

Clinical and Experimental Nephrology

Volumn 7, Issue 3, 2003, Pages 167-171

  Campese, Vito M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CILNIDIPINE; CLONIDINE; CYTOKINE; INTERLEUKIN 1BETA; LOSARTAN; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PHENOL DERIVATIVE;

ADRENERGIC SYSTEM; ADRENERGIC TRANSMISSION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; BRAIN; COLD STRESS; CONTROLLED STUDY; DOWN REGULATION; HYPERTENSION; INTRARENAL DRUG ADMINISTRATION; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY INJURY; KIDNEY NERVE; NERVE STIMULATION; NONHUMAN; NORADRENERGIC SYSTEM; PATHOPHYSIOLOGY; RAT; REVIEW; SODIUM URINE LEVEL; SYMPATHETIC TONE;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION, RENAL; RATS; SYMPATHETIC NERVOUS SYSTEM;

EID: 0141926508     PISSN: 13421751     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10157-003-0238-y     Document Type: Review

References (49)

1. Campese V, Mozayeni P. Pathophysiology of hypertension in specific renal parenchymal diseases. In: Malluche HH, Sawaya BP, Hakim RM, Sayegh MH, editors. Clinical nephrology, dialysis and transplantation. Dustri-Verlag Dr. Karl Feistel; 1999. p. 1-12.
2. Galla JH, Luke RG. Hypertension in renal parenchymal disease. In: Brenner BM, Rector FC. editors. The kidney. WB Saunders; 2000. p. 2035-58.
3. Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, et al. Blood pressure and end-stage renal disease in men. New Engl J Med 1996;334:13-8.
4. Curtis JR, Eastwood JB, Smith EK. Maintenance hemodialysis. Q J Med 1969;38:49-89.
5. Schalekamp MADH, Schalekamp-Kuyken MPA, Demoor-Fruytier M, Meininger T, Vaandrager-Kranenburg DJ, Birk-Enhager WH. Interrelationships between blood pressure, renin, renin substrate and blood, in terminal renal failure. Clin Sci Mol Med 1973;45:417-28.
6. Lazarus JM, Hampers CL, Merrill JP. Hypertension in chronic renal failure. Treatment with hemodialysis and nephrectomy. Arch Intern Med 1974;133:1059-66.
7. Atuk NO, Bailey CJ, Turner S, Peacfi MJ, Westervelt FB Jr. Red blood cell catechol-o-methyl transferase, plasma catecholamines and renin in renal failure. Trans Am Soc Artif Intern Organs 1976;22:195-200.
8. Lake CR, Ziegler MG, Coleman MD, Kopin IJ. Plasma levels of norepinephrine and dopamine-beta-hydroxylase in CRF patients treated with dialysis. Cardiovasc Med 1979;1:1099-111.
9. Henrich WL, Katz FH, Molinoff PB, Schrier RW. Competitive effects of hypokalemia and, depletion on plasma renin activity, aldosterone and catecholamine concentrations in hemodialysis patients. Kidney Int 1977;12:279-84.
10. Izzo JL, Izzo MS, Sterns RH, Freeman RB, Sympathetic nervous system hyperactivity in maintenance hemodialysis patients. Trans Am Soc Artif Organs 1982;28:604-7.
11. Ishii M, Ikeda T, Takagi M. Elevated plasma catecholamines in hypertensives with primary glomerular diseases. Hypertension 1983;5:545-51.
12. Cuche, JL, Prinseau J, Selz F, Ruget G, Baglin A. Plasma free, sulfo-, and glucuro-conjugated catecholamines in uremic patients. Kidney Int 1986;30:566-72.
13. Campese VM, Romoff MS, Levitan D, Lane K, Massry SG. Mechanisms of autonomic nervous system dysfunction in uremia. Kidney Int 1981;20:246-53.
14. Converse RL, Jacobsen TN, Toto RD, Jost CMT, Cosentino F, Fouad-Tarazi F, et al. Sympathetic overactivity in patients with CRF. N Engl J Med 1992;327:1912-8.
15. Bigazzi R, Kogosov E, Campese VM. Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol 1994;4:1901-7.
16. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997;51:722-7.
17. Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis 1995;26:861-5.
18. Recordati G, Moss NG, Genovesi S, Rogenes P. Renal chemoreceptors. J Auton Nerv Syst 1981;3:237-51.
19. Katholi RE. Renal nerves and hypertension: an update. Fed Proc 1985;44:2846-50.
20. Dibona GF. The function of the renal nerves. Rev Physiol Biochem Pharmacol 1982;94:75-181.
21. Calarescu FR, Ciriello J. Renal afferent nerves affect discharge rate of medullary and hypothalamic single units in cat. J Auton Nerv Syst 1981;3:311-20.
22. Ciriello J, Calarescu FR. Central projection of afferent renal fibers in the rat: an anterograde transport study of horseradish peroxidase. J Auton Nerv Syst 1983;8:273-85.
23. Katholi RE, Whitlow PL, Hageman GR, Woods T. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves. J Hypertension 1984;2:349-59.
24. Katholi RE, Winternitz SR, Oparil S. Decrease in peripheral sympathetic nervous system activity following renal denervation or unclipping in the one-kidney one-clip Goldblatt hypertensive rat. J Clin Invest 1982;69:55-62.
25. Brody MJ, Johnson AK. Role of the anteroventral third ventricle region in fluid and electrolyte balance, arterial pressure regulation and hypertension. In: Ganony ML, editor. Frontiers in neuroendocrinology. New York: Raven; 1980. p. 249-92.
26. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffele AC, Koomans HA. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-8.
27. Klein Ihht, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001;12:2427-33.
28. Moss NG, Powell SL, Falk RJ. Intravenous cyclosporine activates afferent and efferent renal nerves and causes sodium retention in innervated kidneys in rats. Proc Natl Acad Sci USA 1985;82:8222-6.
29. Zhang W, Victor RG. Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. Am J Hypertens 2000;13:999-1004.
30. Ye S, Ozgur B, Campese VM. Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. Kidney Int 1997;51:722-7.
31. Ye S, Gumbard M, Campese VM. An acute renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens 1998;11:723-8.
32. Bredt DS, Hwang PM, Snyder SH. Localization of nitric oxide synthase indicating a neuronal role for nitric oxide. Nature 1990;347:768-70.
33. Vincent SR, Kimura H. Histochemical mapping of nitric oxide synthase in the rat brain. Neuroscience 1992;6:755-84.
34. Tseng CJ, Liu HY, Lin HC, Ger LP, Tung CS, Yen MH. Cardiovascular effects of nitric oxide in the brain stem nuclei of rats. Hypertension 1996;27:36-42.
35. Barinaga M. Is nitric oxide the "retrograde messenger"? Science 1991;254:1296-97.
36. Togashi H, Sakuma I, Yoshioka M, Kobayashi T, Yasuda H, Kitabatake A, et al. A central nervous system action of nitric oxide in blood pressure regulation. J Pharmacol Exp Ther 1992;262:343-7.
37. G-methyl-L-arginine, an inhibitor of L-arginine-derived nitric oxide synthesis, stimulates renal sympathetic nerve activity. Circ Res 1992;70:607-11.
38. Ye S, Nosrati S, Campese VM. Nitric oxide (NO) modulates the neurogenic control of blood pressure in rats with chronic renal failure. J Clin Invest 1997;99:540-8.
39. Ye S, Zhong H, Yanamadala V, Campese VM. Renal injury caused by intrarenal injection of phenol increases afferent and efferent renal sympathetic nerve activity. Am J Hypertens 2002;15:717-724.
40. Ruhl A, Hurst S, Collins SM. Synergism between interleukins 1β and 6 on noradrenergic nerves in rat myenteric plexus. Gastroenterology 1994;107:993-1001.
41. Ruhl A, Berezin I, Collins SM. Involvement of eicosanoids and macrophage-like cells in cytokine-mediated changes in rat myenteric nerves. Gastroenterology 1995;109:1852-62.
42. Ichijo T, Katafuchi T, Hori T. Central interleukin-1β enhances splenic sympathetic nerve activity in rats. Brain Res Bull 1994;34:547-53.
43. Terao A, Oikawa M, Saito M. Tissue-specific increase in norepinephrine turnover by central interleukin-1, but not by interleukin-6, in rats. Am J Physiol 1994;266:R400-4.
44. Niijima A, Hori T, Aou S, Oomura Y. The effects of interleukin-1β on the activity of adrenal splenic and renal sympathetic nerves in the rat. J Autonom Nerv Syst 1991;36:183-92.
45. Murakami Y, Yokotani K, Okuma Y, Osumi Y. Nitric oxide mediates central activation of sympathetic outflow induced by interleukin-1β in rats. Eur J Pharmacol 1996;317:61-6.
46. Ye S, Zhong H, Duong VN, Campese VM. Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension 2002;39:1101-6.
47. Campese VM, Ye S, Zhong H. Downregulation of nNOS and interleukin-1β mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension 2002;39(Part 2):519-24.
48. Hosono M, Fujii S, Hiruma T, et al. Inhibitory effect of cilnidipine on vascular sympathetic neurotransmission and subsequent vasoconstriction in spontaneously hypertensive rats. Jpn J Pharmacol 1995;69:127-34.
49. Takahara A, Dohmoto H, Hisa H, Satoh S, Yoshimoto R. Cilnidipine attenuates renal nerve stimulation-induced renal vasoconstriction and antinatriuresis in anesthetized dogs. Jpn J Pharmacol 1997;75:27-32.